key: cord-0969761-04vavfjm
authors: Deana, Cristian; Verriello, Lorenzo; Pauletto, Giada; Corradi, Francesco; Forfori, Francesco; Cammarota, Gianmaria; Bignami, Elena; Vetrugno, Luigi; Bove, Tiziana
title: Insights into neurological dysfunction of critically ill COVID-19 patients
date: 2020-09-15
journal: nan
DOI: 10.1016/j.tacc.2020.09.005
sha: 931079fb0140e9aa1a317e48ee1bec8bccdb549b
doc_id: 969761
cord_uid: 04vavfjm

Novel coronavirus spread rapidly around the world infecting millions of people. It was thus declared a pandemic. This new virus damages the lungs. In the most severe cases, it leads to acute respiratory failure that requires intensive care treatment. However, many clinical reports have listed different neurological symptoms, leading to increased interest in the neurological involvement of COVID-19. Various pathophysiological mechanisms have been proposed to explain these neurological aspects. Direct viral invasion of the nervous system, systemic cytokine storm and severe hypoxemia are key factors in the development of symptoms. Critically ill patients present several additional risk factors for nervous system damage. Reasons for these include deep sedation and extended muscular paralysis, bed rest for several days, and the inability to receive proper physical rehabilitation. After ICU treatment, COVID-19 patients generally require an extensive rehabilitation program. However, distancing restrictions mean that in many cases physiotherapists are unable to enter ICUs, delaying the process of rehabilitation. The role of telemedicine should be considered as an adjunctive tool in the rehabilitation of critically ill COVID-19 patients.

1. Introduction 64 The first case of the novel coronavirus SARS-CoV2, responsible for Coronavirus Disease 19 most frequently used antiviral drugs at the beginning of the pandemic (i.e. chloroquine and 134 hydroxychloroquine) later demonstrated neurological side effects, such as seizures and peripheral 135 neuropathy [19] . 136 Likewise, other drugs used to limit COVID-19 (e.g., lopinavir/ritonavir, azithromycin, interferon, 137 tocilizumab, etc.) are not free from neurological side effects [20, 21] . 138 Nutrition could play a role in neurological involvement. In a recent paper, Battaglini et al. describe 139 the microbiota-gut-brain axis that is considered a regulator of the immune system after acute 140 ischemic stroke [22] . 141 There is a growing body of evidence about gut-brain crosstalk and how gut dysbiosis negatively 142 impacts CNS functioning and vice versa. This is well described in acute ischemic stroke. As in 143 other critically ill patients, gut function in critically ill COVID-19 patients may be impaired, 144 inducing delayed enteral feeding and its associated drawbacks. Similarly, acute CNS damage may 145 impair gut function. 146 Nutrition as a whole could play an important role in maintaining a healthy gut. In addition, 147 immunonutrition (containing ω-3, arginin, RNA) is an intriguing strategy for modulating immune 148 response during the critically ill phase of COVID-19 patients. Unfortunately, however, there is little 149 evidence in support of these claims [23] . mainly ischemic stroke [6] . Acute ischemic stroke associated with COVID-19 can occur both early 155 and later in the course of the disease [9,10]. 156 The pathophysiology and the optimal management of ischemic stroke associated with COVID-19

However, while early therapeutic anticoagulation with LMWH reduces thromboembolism in 168 patients with COVID-19, it must be balanced with the risk of hemorrhagic transformation in 169 patients with acute ischemic stroke. 170 The same mechanism has been proposed to explain cerebral venous thrombosis in COVID-19 171 patients. However this neurological feature has only been described in a few case reports [28, 29] . 172 Unfortunately CT scan and MRI do not reveal any specific cerebral finding in COVID-19 patients. 173 In addition, these exams entail transporting patients across the hospital, with a risk of viral 174 spreading outside the BLUE line (the isolated area dedicated to COVID-19 patients). However, 175 MRIs have revealed ischemic-hypoxic damage and lacunar infarcts, venous thrombosis and strokes 176 [30] . 177 In addition to the findings regarding pulmonary embolism, these demonstrate that such patients 178 require proper anticoagulation. For this reason, telemedicine should be promoted in the context of a pandemic [54] . Infection with COVID-19 may exacerbate known neuromuscular disorders, such us autoimmune 362 diseases (for example chronic inflammatory demyelinating polyneuropathy and myasthenia gravis) 363 and degenerative illnesses. A retrospective study has shown infections to be the leading cause in the 364 exacerbation of myasthenia gravis [81] . It is thus likely that we will see increased rates of disease 365 worsening during the COVID-19 pandemic. physiotherapists, and neuropsychologists [83] . 387 COVID-19 not only damages multiple organs such as the heart, lungs, brain, and kidneys, but also 388 impairs functional activities and self-management. There are no reports about the requirements for 389 post-COVID-19 rehabilitation. However, it is estimated that at least 40% of COVID-19 survivors 390 will present fatigue or weakness after hospital discharge [84] . It is reasonable to assume that about 391 30% of ICU survivors will need facility-based care, while another 20% will require home care [85] . 392 ICU survivors often experience physical and mental effects that persist for months or even years 393 and that lead to reduced quality of life, inability to return to work, and disabilities in daily living 394 [86, 87] . 395 A recent paper reported that up to 80% of patients discharged from the ICU and admitted to 396 rehabilitation facilities present abnormal mini mental status examination (MMSE) or Montreal 397 Cognitive Assessment (MoCA) [83] . This is significant, as these changes have a great impact on 398 their daily lives. As a general principle, rehabilitation should aim at allowing the patients to acquire 399 sufficient autonomy to be discharged into their homes. Pulmonary rehabilitation is required, 400 especially for the non-negligible group of patients undergoing tracheostomy. However, as some 401 patients still test positive for SARS-CoV2 after ICU discharge, the rehabilitation process requires 402 dedicated wards, personnel, and equipment. It is also important to mention that rehabilitation for 403 COVID-19 positive patients should be carried in location isolated from COVID-19 negative 404 patients. However, limited resources mean this is unfortunately not always the case. 405 Again, telemedicine could represent a valid alternative, either in ICU or post-ICU. For instance, 406 since physiotherapists must also continue their work with non-COVID-19 patients, it is important to 407 avoid cross contacts to limit viral spread. Early rehabilitation starting in the ICU under the guidance 408 of physiotherapist who can guide nurses by teleconference or videocalls may hence be an option. 409 There are a number of reports regarding the use of telemedicine during pandemics, although this is 410 not so widespread in ICUs. The acute phase of the COVID-19 pandemic has doubtless been 411 extremely challenging. However, there will also be a post-acute phase, which will have to support 412 J o u r n a l P r e -p r o o f 13 survivors in providing an optimal functional recovery. Only via early rehabilitation programs will 413 we be able to transform ICUs from "delirium factories" to places of proactive recovery and 414 telemedicine may help us to achieve this goal [88, 89] . The COVID-19 pandemic has spread rapidly. In the most severely affected patients, it is a 418 multiorgan disease that mainly involves lungs. However, multiple neurological involvement along 419 time course of the disease has been described frequently (coloured figure 2) . While the 420 pathophysiology is not completely understood, and requires further studies, it seems that COVID- general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. 

Viral etiological causes of febrile seizures for 615 respiratory pathogens (EFES study)

Meningoencephalitis without respiratory failure in a young 618 female patient with COVID-19 infection in Downtown Los Angeles

COVID-19-related acute necrotizing 624 encephalopathy with brain stem involvement in a patient with aplastic anemia

Acute necrotizing encephalopathy with 627

SARS-CoV-2 RNA confirmed in cerebrospinal fluid

Frequent Convulsive Seizures in an Adult 630 Patient with COVID-19: A Case Report

Focal status epilepticus as inique clinical featuyre 633

synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability 651 and fast onset of action

A review of pharmacology and clinical 653 efficacy of brivaracetam

The pharmacokinetics, CNS 656 pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral 657 doses in healthy men

Telemedicine for patients with epilepsy: a pilot 660 experience

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders

Outcome of delirium in critically ill patients: 664 sustematic review and meta-analysis

Delirium in the ICU: an overview

COVID-19: ICU delirium 669 management during SARS.CoV-2 pandemic

Delirium : a missing piece in the COVID-19 pandemic 672 puzzle

COVID-19; a possible role for melatonin in hospitalized patients?

Prophylactic use of exogenous melatonin and 677 melatonine receptor agonists to improve sleep and delirium in the Intensive Care units: a 678 systematic review and meta-analysis of randomized controlled trials

COVID-19: melatonin as a potential adjuvant treatment

Olfactory and gustatory 685 dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease 686 (COVID-19): a multicenter European study

COVID-19 presenting with ophthalmoparesis from 689 cranial nerve palsy

COVID-19 and neuromuscular disorders

Guillain Barre Syndrome

Zika virus infection and Guillain-Barré 695 syndrome: a review focused on clinical and electrophysiological subtypes

Guillain-Barré syndrome associated with 698

-2 infection: causality or coincidence?

COVID-19 may induce Guillain-Barré syndrome

Guillain Barre syndrome associated with COVID-19 infection: A 704 case report

Guillain-Barré syndrome related to COVID-19 708 infection

Early Guillain-Barré syndrome in coronavirus 711 disease 2019 (COVID-19): a case report from an Italian COVID-hospital

Van den Berghe. ICU-acquired weakness

Polyneuropathies in critically ill patients: a 716 prospective evaluation

Incidence and onset of critical illness 719 polyneuropathy in patients with septic shock

Early development of critical illness 722 myopathy and neuropathy in patients with severe sepsis

Review of critical illness myopathy and neuropathy

Intensive insulin therapy in the 727 critically ill patient

The need for neurologists in the care of COVID-732 19 patients

Role of rehabilitation department for 734 adult covid-19 patients: the experience of the San Raffaele Hospital of Milan. ARCHIVES OF 735 PHYSICAL MEDICINE AND REHABILITATION (2020)

Considerations for Postacute Rehabilitation for Survivors of COVID-738 19

Postacute Care Preparedness for COVID-740 19: Thinking Ahead

Return to work after critical illness: a 742 systematic review and meta-analysis

Physical impairments associated with post-745 intensive care syndrome: systematic review based on the world health organization's 746 international classification of functioning, disability and health framework

Exploring the adoption of telemedicine and virtual software for care of

The COVID-19 pandemic: is our medicine still evidence-based?

Neurologic Features in Severe SARS-CoV

COVID-19 patients at a tertiary care centre in India

Loss of smell and Ageusia: Common 760 Findings in COVID-19 Patients

Neurological and neuropsychiatric 763 complications of COVID-19 in 153 patients: a UK-wide surveillance

Association of 766 chemosensory dysfunction and COVID-19 in patients presenting with influenza-like 767 symptoms

Clinical characteristics of 113 deceased patients with 769 coronavirus disease 2019: retrospective study

Time course of loss of smell and dysgeusia in 772 patients with mild SARS-CoV-2 infection

Alterations in Smell or Taste in Mildly 775

Symptomatic Outpatients With SARS-CoV-2 Infection

Self-reported olfactory and taste disorders in